ATE136465T1 - Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis - Google Patents

Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis

Info

Publication number
ATE136465T1
ATE136465T1 AT91900992T AT91900992T ATE136465T1 AT E136465 T1 ATE136465 T1 AT E136465T1 AT 91900992 T AT91900992 T AT 91900992T AT 91900992 T AT91900992 T AT 91900992T AT E136465 T1 ATE136465 T1 AT E136465T1
Authority
AT
Austria
Prior art keywords
prostatitis
treatment
gibberellins
production
medicinal product
Prior art date
Application number
AT91900992T
Other languages
English (en)
Inventor
Per Oden
Original Assignee
Per Oden
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Per Oden filed Critical Per Oden
Application granted granted Critical
Publication of ATE136465T1 publication Critical patent/ATE136465T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/256—Polyterpene radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P27/00—Preparation of compounds containing a gibbane ring system, e.g. gibberellin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
AT91900992T 1989-12-12 1990-12-10 Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis ATE136465T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK627289A DK627289D0 (da) 1989-12-12 1989-12-12 Anvendelse af bicyclononanderivater

Publications (1)

Publication Number Publication Date
ATE136465T1 true ATE136465T1 (de) 1996-04-15

Family

ID=8148421

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91900992T ATE136465T1 (de) 1989-12-12 1990-12-10 Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis

Country Status (11)

Country Link
EP (1) EP0504254B1 (de)
JP (1) JPH05502227A (de)
KR (1) KR920703088A (de)
AT (1) ATE136465T1 (de)
AU (1) AU648529B2 (de)
CA (1) CA2069002A1 (de)
DE (1) DE69026511T2 (de)
DK (1) DK627289D0 (de)
ES (1) ES2087279T3 (de)
NO (1) NO922136L (de)
WO (1) WO1991008751A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0674521T3 (da) * 1992-12-18 2001-09-24 Merck & Co Inc Fremgangsmåde til behandling af kronisk prostatitis med 17beta-N-tertbutylcarbamoyl-4-aza-5a-andost-1-en-3-on
SE9301606D0 (sv) * 1993-05-07 1993-05-07 Per-Christer Oden Composition for the treatment of impaired hair growth
FR2707646A1 (fr) * 1993-07-15 1995-01-20 Univ Toulouse Procédé d'extraction et de purification de saponines hémolytiques.
CA2209315C (en) * 1995-01-06 2009-12-15 Australian Biomedical Company Pty.Ltd. Gibberellins compounds for veterinary and medicinal applications
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
EP1587505B1 (de) * 2002-12-16 2010-07-21 Kimberly-Clark Worldwide, Inc. Wund- und hautpflegezusammensetzungen
US7485666B2 (en) 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
JP5615484B2 (ja) * 2008-01-15 2014-10-29 株式会社 エス・ネット ５α‐リダクターゼ阻害剤
CN102526254B (zh) * 2012-02-08 2013-12-18 李宁 一种治疗男性前列腺炎的中药组合物
JP6761705B2 (ja) * 2016-02-01 2020-09-30 株式会社日本健康食品研究所 ５α−リダクターゼ阻害剤及び泌尿器系疾患治療・予防用組成物ならびにこれらの製造方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424232A (en) * 1982-05-19 1984-01-03 Parkinson Richard W Treatment of herpes simplex

Also Published As

Publication number Publication date
EP0504254A1 (de) 1992-09-23
AU6913891A (en) 1991-07-18
JPH05502227A (ja) 1993-04-22
EP0504254B1 (de) 1996-04-10
NO922136D0 (no) 1992-05-29
NO922136L (no) 1992-05-29
CA2069002A1 (en) 1991-06-13
WO1991008751A1 (en) 1991-06-27
DE69026511D1 (de) 1996-05-15
KR920703088A (ko) 1992-12-17
ES2087279T3 (es) 1996-07-16
DK627289D0 (da) 1989-12-12
DE69026511T2 (de) 1996-11-21
AU648529B2 (en) 1994-04-28

Similar Documents

Publication Publication Date Title
DE3752045D1 (de) Verwendung von Hydroxycarbonsäuren und Derivaten zur Herstellung topischer dermatologischer Zubereitungen zur Behandlung von Falten
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
DE59000270D1 (de) Verwendung von mindestens ein cytokin zur herstellung eines arzneimittels zur systemischen behandlung von praeneoplastischen laesionen.
DE69003652D1 (de) Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.
DE59309043D1 (de) Verfahren zur Herstellung von Pseudolatices und Mikro- oder Nanopartikeln und diese enthaltenden pharmazeutischen Präparaten
DE69011951T2 (de) Verfahren zur Behandlung und Herstellung von Material.
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
ATE136465T1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE3770465D1 (de) Verwendung von zinn-protoporphyrin und zinn-mesoporphyrin zur herstellung eines arzneimittels fuer die behandlung von psoriasis.
DE3850154T2 (de) Verwendung von Gepiron zur Herstellung eines pharmazeutischen Präparats zur Behandlung atypischer Depression.
DE58903917D1 (de) Verwendung des enzym-cofaktors nadph zur herstellung eines arzneimittels sowie daraus hergestelltes arzneimittel und verfahren zu seiner herstellung.
DE3582594D1 (de) Proglumid und dessen pharmazeutische zusammensetzungen zur anwendung bei der behandlung von neoplastischen affektionen.
ATE89728T1 (de) Verwendung von dihydroergotamin und seinen salzen zur lokalen behandlung trophischer stoerungen.
ATE192929T1 (de) Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis
DE68905657T2 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
DE3686097D1 (de) Verwendung von dopamin-agonisten zur herstellung eines arzneimittels zur behandlung von psychostimulant-sucht.
DE68916777D1 (de) Verwendung von TNF zur Herstellung eines Arzneimittels zur Behandlung von Psoriasis.
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
DE69424415T2 (de) Verwendung von efaroxan und dessen derivaten zur herstellung eines arzneimittels zur behandlung parkinsonscher krankheit
DE68905076T2 (de) Pharmazeutische Zusammensetzung für die Behandlung von Hautwunden.
DE69009989D1 (de) Verwendung von chlormethiazol zur herstellung eines artzneimittels zur prophylaxe oder therapie der neurodegeneration.
DE69610045D1 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
DE69021557T2 (de) Verwendung von derivaten von 9,10-dihydrophenanthren zur herstellung eines antitumoralen medikamentes und neuen derivaten daraus.
ATE173921T1 (de) Verwendung von deoxyspergualin zur herstellung eines arzneimittels zur behandlung von entzündlich-hyperreaktiven erkrankungen
DE3777709D1 (de) Verwendung von 3'azido-3'deoxythymidin zur herstellung eines arzneimittels zur behandlung von gardiasis.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties